Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long‐term data of the SIGNS study
- 3 May 2017
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 99 (2) , 169-177
Abstract
Objective: We aimed to describe the current management and outcomes of patients with secondary immunodeficiencies (SID) on intravenous (IV) or subcutaneous (SC) immunoglobulins (IG) as maintenance therapy to prevent infections.Methods: Non‐interventional, prospective study (average follow‐up 20.5 months).Results: Of the 307 SID patients (mean age 63.7±14.4 years, 52% males, in 31% IG newly initiated), 95.4% received IV IG (mean dosing interval 4.6 weeks, average dose 199 mg/kg per 4 weeks) and 4.6% were treated with SC IG (2.6 weeks, 343 mg/kg per 4 weeks). Median IG through level at first documentation was 5.8 g/L and did not differ between IV and SC treatment or between underlying malignancies. In 24.1% of patients, treatment was interrupted temporarily, over a mean of 11.6±6.3 months. In patients with newly initiated IG treatment the 82% overall infection rate prior to treatment dropped to 21% at 1 year.Conclusions: Under clinical practice conditions, IG replacement therapy in SID patients was feasible, diminished infection rates and improved quality of life. Average IG doses were relatively low. Tolerability of IV IG treatment was excellent.Keywords
Funding Information
- Baxter Healthcare Corporation
This publication has 31 references indexed in Scilit:
- Immunoglobulins for primary or secondary immunodeficiency or for immunomodulation in neurological autoimmune diseases: insights from the prospective SIGNS registryJournal of Public Health, 2012
- Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysisLeukemia & Lymphoma, 2009
- Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemiaClinical and Laboratory Haematology, 2008
- Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple MyelomaNew England Journal of Medicine, 2007
- Die Version 2.0 des SF-36 Health Survey - Ergebnisse einer bevölkerungsrepräsentativen StudieInternational Journal of Public Health, 2005
- Bias: Table 1Journal of Epidemiology and Community Health, 2004
- A single European currency for EQ-5D health statesThe European Journal of Health Economics, 2003
- PROPHYLAXIS AGAINST INFECTIONS WITH INTRAVENOUS IMMUN0GLOBULINS IN MULTIPLE MYELOMABritish Journal of Haematology, 1995
- The MOS 36-Item Short-Form Health Survey (SF-36)Medical Care, 1993
- Intravenous Immunoglobulin for the Prevention of Infection in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 1988